Sunday 18 October 2026
Export VYGR’s income statement to Excel — free account
Voyager Therapeutics, Inc.
VYGR Healthcare Biotechnology
Voyager Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $40.4 million, down 49.5% from fiscal 2024. In the quarter to June 2026, revenue fell 39.1%, EPS grew 29.8% and free cash flow grew 24.8%, each against the same quarter a year earlier.
1.90
0.16
−7.77%
Follow VYGR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | 2 | 2 |
+8 more TTM periods Free account |
| (54.09%) | (52.26%) | (48.29%) | (46.09%) | ||
| (41.45%) | (40.74%) | (37.10%) | (35.50%) | ||
ROIC |
(192.55%) | (247.40%) | 0.00% | (804.33%) | |
Return on Tangible Assets |
(89.97%) | (82.29%) | (63.25%) | (64.23%) | |
Average Days of Receivables |
33.41 | 16.45 | 17.29 | 47.05 | |
Free Cash Flow per Share |
(2.01) | (2.18) | (2.30) | (2.02) | |
Free Cash Flow |
(121.42) | (129.94) | (135.06) | (118.86) | |
Capital Expenditures |
(0.85) | (1.95) | (2.60) | (2.12) | |
| Other line items | |||||
Cash ROIC |
(44.85%) | (41.23%) | (34.41%) | (27.72%) | |
Accounts Receivable Turnover |
12.14 | 19.44 | 19.73 | 2.64 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.01 | |
Research and Development Expense of Revenue |
343.77% | 350.06% | 333.57% | 428.87% | |
Selling, General and Administrative Expense of Revenue |
96.31% | 99.10% | 92.99% | 118.86% | |
Share Based Compensation of Revenue |
34.54% | 37.27% | 36.63% | 47.91% | |
Operating CF/Net income |
1.12 | 1.10 | 1.11 | 0.92 | |
Depreciation/Fixed assets |
0.18 | 0.13 | 0.08 | 0.01 | |
Capex/Depreciation |
(0.42) | (1.19) | (2.39) | (32.20) | |
Revenue per Share |
0.57 | 0.61 | 0.69 | 0.53 | |
Operating CF per Share |
(1.99) | (2.15) | (2.26) | (1.99) | |
Capex per Share |
(0.01) | (0.03) | (0.04) | (0.04) | |
Capex to Sales |
0.02 | 0.05 | 0.06 | 0.07 |
Columns are period end dates